The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Alcidion Group (ALC) has signed a $2 million, six-year contract with U.K-based Dartford and Gravesham NHS Trust
  • The contract will roll out the Better OPENeP electronic prescribing and medication management solution
  • This is part of the Paperless at the Point of Care by 2020 nation-wide scheme
  • The information will be fully integrated and enhance clinical decision support
  • Alcidion is up 2.70 per cent today, with shares trading for 19 cents each

Alcidion Group (ALC) has signed a six-year contract with U.K-based Dartford and Gravesham NHS Trust that is valued at £1.02 million (A$1.9 million).

The contract will see Alcidion implement the OPENeP Electronic Prescribing and Medications Administration (ePMA) system produced by Better.

The agreement follows the company’s award back in July, as preferred provider by the Trust to deploy the OPENeP platform.

The agreement also extends Alcidion’s current relationship with Dartford and Gravesham, following the first implementation of the company’s full product suite in the U.K.

Dartford and Gravesham is an NHS Trust strategically planning to achieve full digital maturity by adopting integrated, best-of-breed technology solutions, and being Paperless at the Point of Care by 2020.

“Our approach to improving healthcare delivery is closely aligned with the goals of the Trust and we are excited to demonstrate the effectiveness of the consolidated solution,” Alcidion Managing Director Kate Quirke said.

The Patientrack solution, a bedside patient monitoring software, was implemented earlier this year. Planning is now underway to apply the Miya Precision and Smartpage solutions.

“We were excited by the range of technologies that Alcidion could provide us to achieve our objectives. Alcidion’s partnership with Better allows us to address electronic prescribing and medications management to further complete the picture,” Dartford and Gravesham Director of Digital Transformation Neil Perry said.

The overall aim is to ensure accurate and high-quality treatment for patients.

“By collaborating with Alcidion at Dartford and Gravesham NHS Trust, we aim to create an environment which maximises patient safety, improves collaboration among staff, and prevents unnecessary errors,” Better Business Unit Manager Roko Malkoč said.

The medication management information arising from OPENeP will be fully integrated and will enhance clinical decision support and extending the scope of the electronic patient record.

Alcidion is up 2.70 per cent today, with shares trading for 19 cents each at 10:16 am AEDT.

ALC by the numbers
More From The Market Online

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…
The Market Online Video

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug…

Botanix isn’t sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription…

Singular Health launches upgraded DICOM viewer, with patient-friendly features for engagement with medical records

Singular Health Ltd has launched an upgraded version of its DICOM viewer, set to allow greater…